Syndax (SNDX) announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been accepted for oral ...
Narrows FY24 total operating expenses view to $365M-$370M from $355M-$375M, which includes milestone payments that the Company expects to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback